menu
Branded Generics Market Future Growth, Revenue and Demand
Branded Generics Market Future Growth, Revenue and Demand
The sale will provide sufficient liquidity to Wockhardt to invest in its growing business in India and abroad.

Branded Generics Market Future Growth, Revenue and Demand

Rise in number of mergers and acquisitions is anticipated to help the industry grow in the coming years. For instance, in March 2020, Hyderabad-based pharma major Dr Reddy’s Laboratories bought Wockhardt Ltd.’s branded generics business in India, Nepal, Sri Lanka, Bhutan, and Maldives and its manufacturing plant at Baddi in Himachal Pradesh for around Rs 1,850 crore. Wockhardt is selling a part of the business as it plans to ensure adequate liquidity. Dr Reddy’s is paying more than three times of the revenues that Wockhardt’s business generates.

In 2019, sales of brand name products exceeded $180 million in the United States. As per the terms of the previously announced collaboration agreement, Sol-Gel will receive payments based on product sales from the launch date. In July 2020, Sol-Gel Technologies, Ltd., a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical medicinal products for the treatment of skin diseases, announced today that information provided by Sol-Gel has done An FDA-approved generic drug is expected to launch in the second quarter of 2021.

Explore More Insights@ https://www.alliedmarketresearch.com/request-toc-and-sample/10902

An increase in the number of expired and expiring patents for branded drugs is expected to drive the industry in the coming years. Increasing incidence and population suffering from chronic diseases and disorders will help attract the industry during the forecast period. A major factor affecting this industry is the large number of medicinal products going off patent. This will help in boosting this industry in the coming years.

Over time, Wockhardt's strategic plan is to shift the specialty antibiotic portfolio from acute therapeutic areas to more chronic businesses such as antidiabetic and central nervous system. The sale will provide sufficient liquidity to Wockhardt to invest in its growing business in India and abroad.


Key Market Players

·        ZydusCadila,

·        Teva Pharmaceutical Industries Ltd

·        Mylan N.V.,, Hospira Inc.

·        Dr. Reddy’s Laboratories Ltd

·        Apotex Inc.

·        GlaxoSmithKline Pharmaceuticals Limited

·        Valeant,

·        Sandoz

·        Lupin Pharmaceuticals, Inc.

·        Sanofi,, AstraZeneca.